Dunn A - Search Results

1

Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study.

Warren BB, Thornhill D, Stein J, Fadell M, Ingram JD, Funk S, Norton KL, Lane HD, Bennett CM, Dunn A, Recht M, Shapiro A, Manco-Johnson MJ. Warren BB, et al. Among authors: dunn a. Blood Adv. 2020 Jun 9;4(11):2451-2459. doi: 10.1182/bloodadvances.2019001311. Blood Adv. 2020. PMID: 32492157 Free PMC article. Clinical Trial.

2

Recent advances in the management of the child who has hemophilia.

Dunn AL, Abshire TC. Dunn AL, et al. Hematol Oncol Clin North Am. 2004 Dec;18(6):1249-76, viii. doi: 10.1016/j.hoc.2004.06.016. Hematol Oncol Clin North Am. 2004. PMID: 15511615 Review.

3

Leukemia and P32 radionuclide synovectomy for hemophilic arthropathy.

Dunn AL, Manco-Johnson M, Busch MT, Balark KL, Abshire TC. Dunn AL, et al. J Thromb Haemost. 2005 Jul;3(7):1541-2. doi: 10.1111/j.1538-7836.2005.01447.x. J Thromb Haemost. 2005. PMID: 15978117 Free article. No abstract available.

4

Management and prevention of recurrent hemarthrosis in patients with hemophilia.

Dunn AL. Dunn AL. Curr Opin Hematol. 2005 Sep;12(5):390-4. doi: 10.1097/01.moh.0000169285.66841.c8. Curr Opin Hematol. 2005. PMID: 16093785 Review.

5

Current issues in prophylactic therapy for persons with hemophilia.

Dunn AL, Abshire TC. Dunn AL, et al. Acta Haematol. 2006;115(3-4):162-71. doi: 10.1159/000090930. Acta Haematol. 2006. PMID: 16549891 Review.

6

Recombinant tissue plasminogen activator may reduce frequency of central venous access device infection in hemophilia patients undergoing immune tolerance therapy.

Dunn AL, Abshire TC. Dunn AL, et al. Pediatr Blood Cancer. 2008 Mar;50(3):627-9. doi: 10.1002/pbc.21095. Pediatr Blood Cancer. 2008. PMID: 17143876

7

Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG).

Feldman BM, Funk S, Lundin B, Doria AS, Ljung R, Blanchette V; International Prophylaxis Study Group (IPSG). Feldman BM, et al. Haemophilia. 2008 Jul;14 Suppl 3:162-9. doi: 10.1111/j.1365-2516.2008.01750.x. Haemophilia. 2008. PMID: 18510537 No abstract available.

8

The principal results of the International Immune Tolerance Study: a randomized dose comparison.

Hay CR, DiMichele DM; International Immune Tolerance Study. Hay CR, et al. Blood. 2012 Feb 9;119(6):1335-44. doi: 10.1182/blood-2011-08-369132. Epub 2011 Nov 18. Blood. 2012. PMID: 22101900 Free article. Clinical Trial.

9

F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity.

Miller CH, Benson J, Ellingsen D, Driggers J, Payne A, Kelly FM, Soucie JM, Craig Hooper W; Hemophilia Inhibitor Research Study Investigators. Miller CH, et al. Haemophilia. 2012 May;18(3):375-82. doi: 10.1111/j.1365-2516.2011.02700.x. Epub 2011 Nov 21. Haemophilia. 2012. PMID: 22103590

10

Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance.

Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM; Hemophilia Inhibitor Research Study Investigators. Miller CH, et al. J Thromb Haemost. 2012 Jun;10(6):1055-61. doi: 10.1111/j.1538-7836.2012.04705.x. J Thromb Haemost. 2012. PMID: 22435927 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,982 results

Search Page

Filters